,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2012', 'fs': 'May 2012', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiG2AQ'}, 'Id': 'a0POZ000009oiiG2AQ', 'Event_Date__c': '2012-05-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2012', 'Status_History__c': 'a132P000000Aq11QAC'}, 'change': None}]",May 2012,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2012', 'fs': 'Jun 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiH2AQ'}, 'Id': 'a0POZ000009oiiH2AQ', 'Event_Date__c': '2012-06-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2012', 'Status_History__c': 'a132P000000Aq30QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2012-06.pdf "" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2012-06.pdf "" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2012', 'fs': 'Jun 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Subcommittee at meeting Thursday 7 June 2012.', 'fs': 'Clinical advice received from Cardiovascular Subcommittee at meeting Thursday 7 June 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiJ2AQ'}, 'Id': 'a0POZ000009oiiJ2AQ', 'Event_Date__c': '2012-06-07', 'Event_Description__c': 'Clinical advice received from Cardiovascular Subcommittee at meeting Thursday 7 June 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2012-06.pdf "" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Jun 2012', 'Status_History__c': 'a132P000000Aq3NQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiK2AQ'}, 'Id': 'a0POZ000009oiiK2AQ', 'Event_Date__c': '2012-08-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq4tQAC'}, 'change': None}, {'Summary': {'s': 'The Committee noted that the Subcommittee had reviewed ivabradine for inappropriate sinus tachycardia and recommended that this be reviewed by PTAC once its registration had been approved.', 'fs': 'The Committee noted that the Subcommittee had reviewed ivabradine for inappropriate sinus tachycardia and recommended that this be reviewed by PTAC once its registration had been approved.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-08.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-08.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiL2AQ'}, 'Id': 'a0POZ000009oiiL2AQ', 'Event_Date__c': '2012-08-02', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-08.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Committee noted that the Subcommittee had reviewed ivabradine for inappropriate sinus tachycardia and recommended that this be reviewed by PTAC once its registration had been approved.', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq6oQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Ivabradine is not yet registered.', 'fs': 'Ivabradine is not yet registered.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiM2AQ'}, 'Id': 'a0POZ000009oiiM2AQ', 'Event_Date__c': '2013-05-01', 'Event_Description__c': 'Ivabradine is not yet registered.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqObQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the decrease in use of antiarrhythmics, particularly amiodarone, and considered this was likely due to increased use of devices to treat cardiac arrhythmias and better treatment generally. Members considered it could also be due to more confidence in other agents, such as flecainide, and concerns around amiodarone’s toxicity.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee discussed agents in this class which have little use. Members considered that antiarrhythmics in general did not have good efficacy but there were few alternatives for difficult to treat arrythmias. </p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>Members considered that mexiletine was used by specialists for difficult to treat arrythmias, such as long QT syndrome and some ventricular tachycardias.</p><p><br></p><p>Members considered that disopyramide and propafenone have niche roles such as treatment of hypertrophic cardiomyopathy. However, the Subcommittee also noted that none of its members had personal expertise with this area.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that likely alternatives to mexiletine, disopyramide and propafenone could include prolonged hospital admissions and VT ablation for some patients.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the recent decision to change the funded brands of flecainide. It considered that the consultation on this was good and that the outcome would mean substantial savings. The Subcommittee considered that plasma monitoring could be considered for children. The Subcommittee also considered that patients on flecainide are mainly supported by a GPs and considered that years could go for years without a patient seeing a cardiologist, and that even then they would often be seen by a cardiology nurse instead. Members considered there were marked differences in treatment practice and knowledge around the country. Members considered that ensuring GPs are well informed about the brand change was important.</p><p><br></p><p>The Subcommittee discussed ivabradine, which it had previously recommended funding for inappropriate sinus tachycardia (IST) with a high priority. The Subcommittee also noted that PTAC had recommended that it review ivabradine once its registration had been approved. The Subcommittee also noted that no ivabradine product was registered and that there no applications to Medsafe for registration have been made.</p><p><br></p><p>The Subcommittee considered that since there is a small market for ivabradine, there was little incentive for a supplier to pay the costs of registration. Members considered that because the market was small, the risk from using an unregistered medicine was also small. Members also considered that there remains a high unmet health need for patients with IST intolerant to funded agents, and that ivabradine would provide a health benefit for this niche group of patients. Members considered the group with IST that would access ivabradine if it was funded was likely to be small; potentially being as low as 10 new patients per year.</p><p><br></p><p>The Subcommittee <b>recommended</b> that PHARMAC continue to investigate options to fund ivabradine even if the product was unregistered.\xa0</p>', 'fs': '<p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the decrease in use of antiarrhythmics, particularly amiodarone, and considered this was likely due to increased use of devices to treat cardiac arrhythmias and better treatment generally. Members considered it could also be due to more confidence in other agents, such as flecainide, and concerns around amiodarone’s toxicity.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee discussed agents in this class which have little use. Members considered that antiarrhythmics in general did not have good efficacy but there were few alternatives for difficult to treat arrythmias. </p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>Members considered that mexiletine was used by specialists for difficult to treat arrythmias, such as long QT syndrome and some ventricular tachycardias.</p><p><br></p><p>Members considered that disopyramide and propafenone have niche roles such as treatment of hypertrophic cardiomyopathy. However, the Subcommittee also noted that none of its members had personal expertise with this area.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that likely alternatives to mexiletine, disopyramide and propafenone could include prolonged hospital admissions and VT ablation for some patients.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the recent decision to change the funded brands of flecainide. It considered that the consultation on this was good and that the outcome would mean substantial savings. The Subcommittee considered that plasma monitoring could be considered for children. The Subcommittee also considered that patients on flecainide are mainly supported by a GPs and considered that years could go for years without a patient seeing a cardiologist, and that even then they would often be seen by a cardiology nurse instead. Members considered there were marked differences in treatment practice and knowledge around the country. Members considered that ensuring GPs are well informed about the brand change was important.</p><p><br></p><p>The Subcommittee discussed ivabradine, which it had previously recommended funding for inappropriate sinus tachycardia (IST) with a high priority. The Subcommittee also noted that PTAC had recommended that it review ivabradine once its registration had been approved. The Subcommittee also noted that no ivabradine product was registered and that there no applications to Medsafe for registration have been made.</p><p><br></p><p>The Subcommittee considered that since there is a small market for ivabradine, there was little incentive for a supplier to pay the costs of registration. Members considered that because the market was small, the risk from using an unregistered medicine was also small. Members also considered that there remains a high unmet health need for patients with IST intolerant to funded agents, and that ivabradine would provide a health benefit for this niche group of patients. Members considered the group with IST that would access ivabradine if it was funded was likely to be small; potentially being as low as 10 new patients per year.</p><p><br></p><p>The Subcommittee <b>recommended</b> that PHARMAC continue to investigate options to fund ivabradine even if the product was unregistered.\xa0</p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-Cardiovascular-Subcommittee-Minutes-2019-05.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-Cardiovascular-Subcommittee-Minutes-2019-05.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 8 May 2019.', 'fs': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 8 May 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiN2AQ'}, 'Id': 'a0POZ000009oiiN2AQ', 'Event_Date__c': '2019-05-08', 'Event_Description__c': 'Clinical advice received from Cardiovascular Subcommittee at meeting Wednesday 8 May 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-Cardiovascular-Subcommittee-Minutes-2019-05.pdf"" target=""_blank"">Cardiovascular Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'May 2019', 'Published_Discussion__c': '<p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the decrease in use of antiarrhythmics, particularly amiodarone, and considered this was likely due to increased use of devices to treat cardiac arrhythmias and better treatment generally. Members considered it could also be due to more confidence in other agents, such as flecainide, and concerns around amiodarone’s toxicity.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee discussed agents in this class which have little use. Members considered that antiarrhythmics in general did not have good efficacy but there were few alternatives for difficult to treat arrythmias. </p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>Members considered that mexiletine was used by specialists for difficult to treat arrythmias, such as long QT syndrome and some ventricular tachycardias.</p><p><br></p><p>Members considered that disopyramide and propafenone have niche roles such as treatment of hypertrophic cardiomyopathy. However, the Subcommittee also noted that none of its members had personal expertise with this area.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that likely alternatives to mexiletine, disopyramide and propafenone could include prolonged hospital admissions and VT ablation for some patients.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the recent decision to change the funded brands of flecainide. It considered that the consultation on this was good and that the outcome would mean substantial savings. The Subcommittee considered that plasma monitoring could be considered for children. The Subcommittee also considered that patients on flecainide are mainly supported by a GPs and considered that years could go for years without a patient seeing a cardiologist, and that even then they would often be seen by a cardiology nurse instead. Members considered there were marked differences in treatment practice and knowledge around the country. Members considered that ensuring GPs are well informed about the brand change was important.</p><p><br></p><p>The Subcommittee discussed ivabradine, which it had previously recommended funding for inappropriate sinus tachycardia (IST) with a high priority. The Subcommittee also noted that PTAC had recommended that it review ivabradine once its registration had been approved. The Subcommittee also noted that no ivabradine product was registered and that there no applications to Medsafe for registration have been made.</p><p><br></p><p>The Subcommittee considered that since there is a small market for ivabradine, there was little incentive for a supplier to pay the costs of registration. Members considered that because the market was small, the risk from using an unregistered medicine was also small. Members also considered that there remains a high unmet health need for patients with IST intolerant to funded agents, and that ivabradine would provide a health benefit for this niche group of patients. Members considered the group with IST that would access ivabradine if it was funded was likely to be small; potentially being as low as 10 new patients per year.</p><p><br></p><p>The Subcommittee <b>recommended</b> that PHARMAC continue to investigate options to fund ivabradine even if the product was unregistered.\xa0</p>', 'Status_History__c': 'a132P000000ArfGQAS'}, 'change': None}]",Jun 2012,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2012', 'fs': 'Jun 2012', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009oiiI2AQ'}, 'Id': 'a0POZ000009oiiI2AQ', 'Event_Date__c': '2012-06-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jun 2012', 'Status_History__c': 'a132P000000Aq36QAC'}, 'change': None}]",Jun 2012,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
